Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

AMRantimicrobial resistancechronic lung diseasechronic respiratory diseasechronic pulmonary diseasechronic respiratory conditionshigh-priority pathogens

Outcome Measures

Primary Outcomes (1)

Prevalence of antimicrobial resistance in chronic lung diseases
Prevalence and burden of antimicrobial resistance in chronic lung diseases at both local and global levels.
Five years from the beginning of the study.

Secondary Outcomes (3)

The antimicrobial susceptibility profile of high-priority resistant pathogens
Five years from the beginning of the study.
The geographical variation in the prevalence of antimicrobial resistance
Five years from the beginning of the study
The risk factors for antimicrobial resistance in chronic lung diseases.
Five years from the beginning of the study

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The study will include patients of all ages with all kinds of chronic lung disease who underwent testing of at least one respiratory sample in the previous 12 months who attend a respiratory outpatient clinic or are hospitalized during the yearly two two-weeks recruitment windows.

You may qualify if:

Patients of all ages with any chronic lung disease who, for clinical practice, underwent testingof at least one respiratory biological sample (sputum culture; bronchoaspirate; bronchoalveolar lavage; nasal swab; throat swab) within the 12 months prior to the visit.

Sponsors & Collaborators

European Respiratory Society
Othercollaborator
Royal Brompton & Harefield NHS Foundation Trust
Othercollaborator
Imperial College London

Study Sites (68)

University of Michigan

Ann Arbor, Michigan, 48109, United States

RECRUITING

Shijing JiaCONTACT

Catholic University Our Lady of Good Counsel

Tirana, Albania

RECRUITING

Malvina HoxhaCONTACT

Frankston Hospital

Frankston, Australia

RECRUITING

Study Officials

Andrea Gramegna
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
PRINCIPAL INVESTIGATOR

Central Study Contacts

Andrea Gramegna

CONTACT

0255032020 andrea.gramegna@unimi.it

Chiara Premuda

CONTACT

0255032020

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 5 Years
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 8, 2026

First Posted

October 14, 2026

Study Start

March 31, 2025

Actual (reported)

Primary Completion

November 2029

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (68)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (68)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations